Rocket Lab’s Two-Front War: Insider Sales and Sector Contagion Overshadow a $266 Million Space Force Win
Published on 07/29/2026 at 13:51 | Redaktion boerse-global.de
Rocket Lab’s share price is caught in a punishing tug-of-war. On one side, a record $266 million contract with the U.S. Space Force and a growing institutional footprint. On the other, a sector-wide downdraft fueled by SpaceX’s lockup expiry, insider selling by the company’s own founder, and mounting anxiety over the debt burden tied to the Iridium acquisition.
The stock closed at €55.10 on Wednesday, down 1.6% on the day, extending a 30-day slide that has erased nearly 36% of its value. The decline has been relentless: from a 52-week high of €133.80 reached in late May, the shares have fallen roughly 59%. The 14-day relative strength index now sits at 31.9, flirting with oversold territory. Yet buyers remain largely on the sidelines.
Institutions Move In as Retail Exits
Behind the curtain, however, a different story is unfolding. Regulatory filings published on July 29 reveal that the Bank of Nova Scotia increased its Rocket Lab position by a staggering 149.8%. The timing is notable: the institution chose to load up precisely during the stock’s deepest weakness, a pattern that suggests long-term conviction rather than short-term momentum chasing.
This institutional buying runs counter to the prevailing market sentiment. Rocket Lab’s year-to-date performance still shows a 45% gain, a reminder that the company’s backlog of government and commercial contracts continues to grow. The disconnect between operational momentum and share price action has rarely been wider.
Should investors sell immediately? Or is it worth buying Rocket Lab?
The SpaceX Shadow
The primary culprit for the sell-off appears to be sector contagion. SpaceX, the industry’s dominant player, is approaching the expiration of its lockup period on August 6. Reports indicate that SpaceX shares are already trading below their IPO price of $135. When the sector leader wobbles, it drags the entire peer group lower — regardless of individual fundamentals.
Rocket Lab finds itself painted with the same brush as more speculative competitors, even as its own order book swells. The company recently secured a fixed-price, $266 million contract with the U.S. Space Force for up to 18 suborbital HASTE launches through 2028. Separately, the Trump administration has proposed regulatory reforms that would exempt the FAA from certain environmental reviews, potentially accelerating commercial launch approvals. The industry projects more than 500 launches annually by 2036 — a structural tailwind for any vertically integrated operator.
The Iridium Calculus
The market’s skepticism, however, is not entirely external. Rocket Lab’s $8 billion acquisition of Iridium Communications — a deal that transforms the company from a pure launch provider into a vertically integrated satellite operator with a 66-satellite network and over 2.5 million subscribers — carries a significant near-term cost. Investors are fixated on the bridge financing, potential capital raises, and dilution risk that come with the transaction.
Compounding those concerns, CEO Peter Beck’s Equatorial Trust sold 3.28 million shares between July 6 and July 8, generating proceeds of roughly $286.4 million. The sales were executed through a pre-arranged 10b5-1 trading plan, making them legally compliant and long-planned. In a nervous market, however, insider sales are rarely interpreted as a vote of confidence, regardless of the documentation.
Analyst Conviction vs. Market Reality
The gap between Wall Street’s view and the stock’s actual performance is unusually wide. Citizens maintained its “Market Outperform” rating with a $130 price target, citing progress on the Neutron rocket and the strategic logic of the Iridium deal. The consensus analyst target stands at $114.33, or roughly €100.52 — implying nearly 80% upside from current levels.
Yet the stock now trades almost 17% below its 200-day moving average of €67.39. The technical trend remains firmly downward, even as the fundamental narrative points upward.
Rocket Lab at a turning point? This analysis reveals what investors need to know now.
Two Scenarios, One Pivot Point
Three developments will shape the next leg of Rocket Lab’s story: the integration of Iridium, continued testing of the Archimedes engine and structural components for the Neutron rocket (first flight targeted for late 2026), and the company’s deepening role in national security missions, exemplified by the record-fast Victus Haze mission on July 7.
The next major catalyst arrives on August 10, when Rocket Lab reports second-quarter results after the U.S. market close. Investors will be looking for details on Iridium integration costs, the capital expenditure plan for the Alaska launch site expansion, and any updates on the Neutron timeline.
Until then, the stock exists in two competing realities. In one, the Iridium integration and Space Force contracts justify a market capitalization of roughly €35 billion. In the other, the capital-intensive Neutron development and acquisition debt consume any optimism. The resolution of that tension may begin to emerge after the SpaceX lockup expires on August 6 and Rocket Lab delivers its quarterly report four days later.
Ad
Rocket Lab Stock: New Analysis - 29 July
Fresh Rocket Lab information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
